ScreenerHero

EYPT EyePoint, Inc.

NAS · US · Healthcare · Biotechnology · eyepoint.bio
3.320USD+4.73%Mkt Cap: 286.22M $P/E: —

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap286.22M USD
Enterprise Value115.19M USD
Revenue (TTM)2.79M USD
Gross Profit29.30M USD
Net Income (TTM)-231.96M USD
Revenue/Share0.03 USD
Last Price3.320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees214
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.15
PEG—
EV/EBITDA-0.37
EV/Revenue41.32
P/S98.02
P/B1.62
EPS (TTM)-3.78
EPS (Forward)-2.76
52W Range
3.0502% of range19.11
52W High19.11 USD
52W Low3.050 USD
Profitability
Gross Margin93.41%
Oper. Margin-19207.10%
EBITDA Margin0.00%
Profit Margin-739.42%
ROE-75.78%
ROA-63.73%
Growth
Revenue Growth-90.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-240.11M USD
CapEx (TTM)3.28M USD
FCF Margin-5559.92%
FCF Yield-54.16%
Net Debt-158.10M USD
Net Debt/EBITDA0.50
Balance Sheet
Debt/Equity0.07
Current Ratio4.50
Quick Ratio4.30
Book Value/Sh1.96 USD
Cash/Share2.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 9, 2020
Splits
Last Split1:10
Split DateDec 9, 2020
Analyst Consensus
Rating—
Target (Mean)25.91 USD
Upside (mean)+680.4%
Target Range4.000 USD – 68.00 USD
4.000+680.4% to mean68.00
# Analysts11
Ownership
Shares Out.86.21M
Float60.67M
Insiders3.52%
Institutions117.64%
Short Interest
Short Ratio2.8d
Short % Float24.18%
Short % Out.22.98%
Shares Short19.81M
Short (prev mo.)18.43M
Technical
SMA 506.655 (-50.1%)
SMA 20012.40 (-73.2%)
Beta1.68
S&P 52W Chg16.45%
Avg Vol (30d)5.25M
Avg Vol (10d)2.66M
Technical Indicators
RSI (14)31.1
MACD-1.1411
MACD Signal-1.3827
MACD Hist.+0.2416
BB Upper4.617 USD
BB Middle3.707 USD
BB Lower2.796 USD
BB Width49.11%
ATR (14)0.4698 USD
Vol Ratio (20d)0.95x